Abatacept therapy and safety management

https://doi.org/10.1016/S1297-319X(09)74520-8Get rights and content

Abstract

Objectives

To elaborate a how-to-use abatacept material intended to help physicians in the management of patients with inflammatory diseases treated with this drug in routine practice.

Methods

1) Selection of the relevant domains by a rheumatologists’ panel; 2) Search for published evidence in each domain; 3) Elaboration of the clinical tool guide with a 3-level gradation of evidence (evidence-based medicine EBM, official recommendations and expert's opinion). The experts were 11 academic rheumatologists with a large experience in prescribing abatacept and in managing rheumatoid arthritis. They were all members of the CRI (Club Rhumatismes et Inflammation), a section of the French Rheumatology Society dedicated to the inflammatory rheumatic diseases. Each fact sheet was reviewed by two other experts; 4) Regular updating based on medical literature and postmarketing surveillance data.

Results

Four domains were considered relevant: abatacept contraindications, management of side effects or associated diseases appearing during abatacept treatment, management of “practical situations” such as surgery or pregnancy, physician and patient information.

After the literature analysis and discussion during an experts’ meeting, a consensus was reached on:

  • a pre-treatment checklist aimed at searching abatacept contraindications;

  • a what-to-do document when facing side effects or associated diseases (autoimmune pathology, bacterial or viral infections, cardiovascular diseases, intolerance to abatacept, solid or haematological malignancy) or “practical situations” (surgery, pregnancy, vaccination, travel, drug-drug interactions);

  • an example of standard information letter to be addressed to the attending physician (rheumatologist and general practitioner);

  • an example of standard information letter to be addressed to the patient.

Conclusion

Based on both an EBM approach and an expert's opinion approach, this abatacept clinical tool guide should provide assistance to all physicians attending patients treated with abatacept. For a better implementation in clinical practice, this tool guide will be available online at www.cri-net.com and regularly updated.

References (61)

  • T. Schaeverbeke et al.

    Étude de la réponse immunitaire au vaccin antigrippal chez les patients ayant une polyarthrite rhumatoïde et traités par abatacept

    Rev Rheum

    (2007)
  • D.C. Tong et al.

    Antibiotic prophylaxis in dentistry: a review and practice recommendations

    J Am Dent Assoc

    (2000)
  • T. Pham et al.

    Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammation (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR)

    Joint Bone Spine

    (2005)
  • T. Pham et al.

    Rituximab (Mabthera) therapy and safety management. Clinical tool guide elaborated by the Rheumatic Diseases and inflammation Group (Club Rhumatismes et Inflammation, CRI), of the French Society of Rheumatology (Société Française de Rhumatologie, SFR)

    Joint Bone Spine

    (2008)
  • J.M. Kremer et al.

    Time to treatment response with abatacept in patients with rheumatoid arhritis and an inadequate response to methotrexate

    Arthritis Rheum

    (2008)
  • M. Schiff et al.

    Time to treatment response with abatacept in patients with RA and an inadequate response to anti-TNF therapy

    Arthritis Rheum

    (2008)
  • M. Genovese et al.

    Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition

    N Engl J Med

    (2005)
  • C.A. Hunter et al.

    Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma

    Immunol Res

    (2003)
  • E. Marks et al.

    Differential CD28 and inducible costimulatory molecule signalling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection

    Infect Immun

    (2007)
  • C.L. Bigbee et al.

    Abatacept treatment does not exacerbate chronic mycobacterium tuberculosis infection in mice

    Arthritis Rheum

    (2007)
  • H.G. Haggerty et al.

    Utilization of host resistance models (HRMs) in the prediction of human safety of abatacept (ABA): a translational approach

    Arthritis Rheum

    (2007)
  • J. Sibilia et al.

    Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis

    Clin Exp Rheumatol

    (2007)
  • CHMP review of data on quality, safety and efficacy of abatacept. EMEA 2007....
  • Briefing document for abatacept (BMS – 188667). FDA Arthritis Advisory Committee. 6 September 2005....
  • Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for...
  • A. Smitten et al.

    Hospitalized infections in the abatacept RA clinical development program: an updated epidemiological assessment with >10,000 person-years of exposure

    Arthritis Rheum

    (2008)
  • Prévention et prise en charge des tuberculoses survenant sous anti-TNF·. AFSSAPS Juillet 2005....
  • D.E. Furst et al.

    Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

    Ann Rheum Dis

    (2007)
  • J.M. Kremer et al.

    Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlledtrial

    Arthritis and rheumatism

    (2005)
  • J.M. Kremer et al.

    Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial

    Annals of internal medicine

    (2006)
  • Cited by (41)

    • Immunosuppression, rheumatic diseases, multiple sclerosis, and Wilson's disease

      2015, Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Third Edition
    • Safety of biologics: Elaboration and validation of a questionnaire assessing patients' self-care safety skills: The BioSecure questionnaire. An initiative of the French Rheumatology Society Therapeutic Education section

      2013, Joint Bone Spine
      Citation Excerpt :

      A steering group of 10 rheumatologists, one pharmacist and two allied health professionals specialized in biologics or in patient education elaborated an exhaustive list of skills which could be useful to deal with safety issues of biologics. The list was developed based on the data available in the literature, including follow-up and management of biologics national and international recommendations [2,6–16], and expert opinion. The literature accessed in 2009 related to tumor necrosis factor inhibitors, rituximab and abatacept; however, later in the process, data regarding tocilizumab were also searched to ensure the list of skills is applicable to all currently available biologics [17].

    • Screening of tuberculosis before biologics

      2012, Medecine et Maladies Infectieuses
      Citation Excerpt :

      Sixty-nine cases of tuberculosis were observed (36 under infliximab, 28 under adalimumab, and 5 under etanercept) with a relative risk of 13.3 [95% CI 2.6–69.0] for infliximab, and 17.1 [95% CI 3.6–80.6] for adalimumab compared to etanercept [5]. There is no clearly identified increase of risk for tuberculosis in trials on abatacept and tocilizumab [2–4]. This does not mean there is no increase of risk since in all trials tuberculosis was screened for.

    View all citing articles on Scopus
    View full text